Senseonics Initiates First-In-Human Study Of Freedom
First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028Built on the proven sensing technology behind
Share
Why It Matters
Senseonics is testing a new glucose monitor that lasts a whole year. Watch to see if the company hits its 2028 launch target and what doctors think.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.